Research ArticleOriginal Article

Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer

Qiong Wang, Zean Li, Jin Yang, Shirong Peng, Qianghua Zhou, Kai Yao, Wenli Cai, Zhongqiu Xie, Fujun Qin, Hui Li, Xu Chen, Kaiwen Li and Hai Huang
Cancer Biology & Medicine August 2022, 19 (8) 1193-1210; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0550

References

  1. 1.↵
    2. Watson PA,
    3. Arora VK,
    4. Sawyers CL.
    Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015; 15: 701–11.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Chandrasekar T,
    3. Yang JC,
    4. Gao AC,
    5. Evans CP.
    Mechanisms of resistance in castration-resistant prostate cancer (crpc). Transl Androl Urol. 2015; 4: 365–80.
    OpenUrlCrossRef
  3. 3.↵
    2. Zhao N,
    3. Peacock SO,
    4. Lo CH,
    5. Heidman LM,
    6. Rice MA,
    7. Fahrenholtz CD, et al.
    Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. Sci Transl Med. 2019; 11: eaaw4636.
  4. 4.↵
    2. Wang Q,
    3. Li W,
    4. Zhang Y,
    5. Yuan X,
    6. Xu K,
    7. Yu J, et al.
    Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009; 138: 245–56.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    2. Cornford P,
    3. Bellmunt J,
    4. Bolla M,
    5. Briers E,
    6. De Santis M,
    7. Gross T, et al.
    Eau-estro-siog guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017; 71: 630–42.
    OpenUrl
  6. 6.↵
    2. Francini E,
    3. Gray KP,
    4. Shaw GK,
    5. Evan CP,
    6. Hamid AA,
    7. Perry CE, et al.
    Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer Prostatic Dis. 2019; 22: 420–7.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Scher HI,
    3. Fizazi K,
    4. Saad F,
    5. Taplin ME,
    6. Sternberg CN,
    7. Miller K, et al.
    Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367: 1187–97.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    2. Ryan CJ,
    3. Smith MR,
    4. de Bono JS,
    5. Molina A,
    6. Logothetis CJ,
    7. de Souza P, et al.
    Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368: 138–48.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    2. Aparicio A,
    3. Logothetis CJ,
    4. Maity SN.
    Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov. 2011; 1: 466–8.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    2. Wang W,
    3. Epstein JI.
    Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008; 32: 65–71.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    2. Nadal R,
    3. Schweizer M,
    4. Kryvenko ON,
    5. Epstein JI,
    6. Eisenberger MA.
    Small cell carcinoma of the prostate. Nat Rev Urol. 2014; 11: 213–9.
    OpenUrlCrossRefPubMed
  12. 12.↵
    2. Komura K,
    3. Jeong SH,
    4. Hinohara K,
    5. Qu F,
    6. Wang X,
    7. Hiraki M, et al.
    Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of kdm5d expression. Proc Natl Acad Sci U S A. 2016; 113: 6259–64.
    OpenUrlAbstract/FREE Full Text
  13. 13.
    2. Pignot G,
    3. Maillet D,
    4. Gross E,
    5. Barthelemy P,
    6. Beauval JB,
    7. Constans-Schlurmann F, et al.
    Systemic treatments for high-risk localized prostate cancer. Nat Rev Urol. 2018; 15: 498–510.
    OpenUrl
  14. 14.↵
    2. Carceles-Cordon M,
    3. Kelly WK,
    4. Gomella L,
    5. Knudsen KE,
    6. Rodriguez-Bravo V,
    7. Domingo-Domenech J.
    Cellular rewiring in lethal prostate cancer: The architect of drug resistance. Nat Rev Urol. 2020; 17: 292–307.
    OpenUrl
  15. 15.↵
    2. Gu P,
    3. Chen X,
    4. Xie R,
    5. Han J,
    6. Xie W,
    7. Wang B, et al.
    Lncrna hoxd-as1 regulates proliferation and chemo-resistance of castration-resistant prostate cancer via recruiting wdr5. Mol Ther. 2017; 25: 1959–73.
    OpenUrl
  16. 16.↵
    2. Bandaru V,
    3. Sunkara S,
    4. Wallace SS,
    5. Bond JP.
    A novel human DNA glycosylase that removes oxidative DNA damage and is homologous to escherichia coli endonuclease viii. DNA Repair (Amst). 2002; 1: 517–29.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Semlow DR,
    3. Zhang J,
    4. Budzowska M,
    5. Drohat AC,
    6. Walter JC.
    Replication-dependent unhooking of DNA interstrand cross-links by the neil3 glycosylase. Cell. 2016; 167: 498–511.
    OpenUrlCrossRefPubMed
  18. 18.↵
    2. Li N,
    3. Wang J,
    4. Wallace SS,
    5. Chen J,
    6. Zhou J,
    7. D’Andrea AD.
    Cooperation of the neil3 and fanconi anemia/brca pathways in interstrand crosslink repair. Nucleic Acids Res. 2020; 48: 3014–28.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Olsen MB,
    3. Hildrestrand GA,
    4. Scheffler K,
    5. Vinge LE,
    6. Alfsnes K,
    7. Palibrk V, et al.
    Neil3-dependent regulation of cardiac fibroblast proliferation prevents myocardial rupture. Cell Rep. 2017; 18: 82–92.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Yadav S,
    3. Anbalagan M,
    4. Baddoo M,
    5. Chellamuthu VK,
    6. Mukhopadhyay S,
    7. Woods C, et al.
    Somatic mutations in the DNA repairome in prostate cancers in african americans and caucasians. Oncogene. 2020; 39: 4299–311.
    OpenUrlCrossRef
  21. 21.↵
    2. Kim YS,
    3. Kim Y,
    4. Choi JW,
    5. Oh HE,
    6. Lee JH.
    Genetic variants and risk of prostate cancer using pathway analysis of a genome-wide association study. Neoplasma. 2016; 63: 629–34.
    OpenUrl
  22. 22.↵
    2. Beltran H,
    3. Rickman DS,
    4. Park K,
    5. Chae SS,
    6. Sboner A,
    7. MacDonald TY, et al.
    Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011; 1: 487–95.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    2. Yadav SS,
    3. Li J,
    4. Stockert JA,
    5. Herzog B,
    6. O’Connor J,
    7. Garzon-Manco L, et al.
    Induction of neuroendocrine differentiation in prostate cancer cells by dovitinib (tki-258) and its therapeutic implications. Transl Oncol. 2017; 10: 357–66.
    OpenUrl
  24. 24.↵
    2. Gu P,
    3. Chen X,
    4. Xie R,
    5. Xie W,
    6. Huang L,
    7. Dong W, et al.
    A novel ar translational regulator lncrna lbcs inhibits castration resistance of prostate cancer. Mol Cancer. 2019; 18: 109.
    OpenUrl
  25. 25.↵
    2. Xie M,
    3. Vesuna F,
    4. Tantravedi S,
    5. Bol GM,
    6. Heerma van Voss MR,
    7. Nugent K, et al.
    Rk-33 radiosensitizes prostate cancer cells by blocking the rna helicase ddx3. Cancer Res. 2016; 76: 6340–50.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    2. El Bezawy R,
    3. Cominetti D,
    4. Fenderico N,
    5. Zuco V,
    6. Beretta GL,
    7. Dugo M, et al.
    Mir-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the egfr-zeb1 axis. Cancer Lett. 2017; 395: 53–62.
    OpenUrl
  27. 27.↵
    2. Pignatta S,
    3. Arienti C,
    4. Zoli W,
    5. Di Donato M,
    6. Castoria G,
    7. Gabucci E, et al.
    Prolonged exposure to (r)-bicalutamide generates a lncap subclone with alteration of mitochondrial genome. Mol Cell Endocrinol. 2014; 382: 314–24.
    OpenUrl
  28. 28.↵
    2. Xu P,
    3. Zhou Z,
    4. Xiong M,
    5. Zou W,
    6. Deng X,
    7. Ganaie SS, et al.
    Parvovirus b19 ns1 protein induces cell cycle arrest at g2-phase by activating the atr-cdc25c-cdk1 pathway. PLoS Pathog. 2017; 13: e1006266.
  29. 29.↵
    2. Ding L,
    3. Madamsetty VS,
    4. Kiers S,
    5. Alekhina O,
    6. Ugolkov A,
    7. Dube J, et al.
    Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to chemotherapy by abrogating the topbp1/atr-mediated DNA damage response. Clin Cancer Res. 2019; 25: 6452–62.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    2. Siegel RL,
    3. Miller KD,
    4. Jemal A.
    Cancer statistics, 2018. CA Cancer J Clin. 2018; 68: 7–30.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Rohrer Bley C,
    3. Furmanova P,
    4. Orlowski K,
    5. Grosse N,
    6. Broggini-Tenzer A,
    7. McSheehy PM, et al.
    Microtubule stabilising agents and ionising radiation: Multiple exploitable mechanisms for combined treatment. Eur J Cancer. 2013; 49: 245–53.
    OpenUrl
  32. 32.↵
    2. Maity A,
    3. McKenna WG,
    4. Muschel RJ.
    The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol. 1994; 31: 1–13.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    2. Wallace BD,
    3. Berman Z,
    4. Mueller GA,
    5. Lin Y,
    6. Chang T,
    7. Andres SN, et al.
    Ape2 zf-grf facilitates 3’-5’ resection of DNA damage following oxidative stress. Proc Natl Acad Sci U S A. 2017; 114: 304–9.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    2. Klattenhoff AW,
    3. Thakur M,
    4. Chu CS,
    5. Ray D,
    6. Habib SL,
    7. Kidane D.
    Loss of neil3 DNA glycosylase markedly increases replication associated double strand breaks and enhances sensitivity to atr inhibitor in glioblastoma cells. Oncotarget. 2017; 8: 112942–58.
    OpenUrlCrossRefPubMed
  35. 35.↵
    2. Shinmura K,
    3. Kato H,
    4. Kawanishi Y,
    5. Igarashi H,
    6. Goto M,
    7. Tao H, et al.
    Abnormal expressions of DNA glycosylase genes neil1, neil2, and neil3 are associated with somatic mutation loads in human cancer. Oxid Med Cell Longev. 2016; 2016: 1546392.
  36. 36.↵
    2. Massaad MJ,
    3. Zhou J,
    4. Tsuchimoto D,
    5. Chou J,
    6. Jabara H,
    7. Janssen E, et al.
    Deficiency of base excision repair enzyme neil3 drives increased predisposition to autoimmunity. J Clin Invest. 2016; 126: 4219–36.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords